HC Wainwright Reaffirms “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $21.00 target price on the stock.

A number of other analysts also recently issued reports on the company. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

PDS Biotechnology Trading Down 10.7 %

Shares of PDS Biotechnology stock opened at $2.01 on Friday. The stock has a 50 day moving average of $3.21 and a 200 day moving average of $3.26. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84. The firm has a market capitalization of $74.01 million, a price-to-earnings ratio of -1.65 and a beta of 1.93. PDS Biotechnology has a fifty-two week low of $1.53 and a fifty-two week high of $6.85.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors have recently bought and sold shares of the company. Tempus Wealth Planning LLC purchased a new position in shares of PDS Biotechnology in the second quarter valued at approximately $55,000. Ground Swell Capital LLC acquired a new stake in PDS Biotechnology during the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in PDS Biotechnology in the 2nd quarter valued at approximately $115,000. Squarepoint Ops LLC acquired a new position in shares of PDS Biotechnology in the second quarter worth $120,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of PDS Biotechnology during the second quarter worth $146,000. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.